Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension
Akshay S. Desai, Adam D. Karns, Jolita Badarienė, Ahmad Aswad et autres
Importance: In prior monotherapy studies of patients with hypertension, single subcutaneous doses of zilebesiran, an investigational RNA interference therapeutic, reduced serum angiotensinogen levels and systolic blood pressure (SBP) at 3 and 6 months. Objective: To evaluate the efficacy and safety of zilebesiran …
us, lt, gb (code pays fourni par la source)